Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Inventory: 2013-2025

Historic Inventory for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $185.9 million.

  • Amphastar Pharmaceuticals' Inventory rose 42.68% to $185.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.9 million, marking a year-over-year increase of 42.68%. This contributed to the annual value of $153.7 million for FY2024, which is 45.27% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Inventory of $185.9 million as of Q3 2025, which was down 3.02% from $191.7 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Inventory ranged from a high of $191.7 million in Q2 2025 and a low of $92.8 million during Q4 2021.
  • Moreover, its 3-year median value for Inventory was $122.4 million (2024), whereas its average is $137.2 million.
  • Its Inventory has fluctuated over the past 5 years, first decreased by 10.00% in 2021, then spiked by 60.59% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Inventory (Quarterly) stood at $92.8 million in 2021, then grew by 11.61% to $103.6 million in 2022, then rose by 2.17% to $105.8 million in 2023, then soared by 45.27% to $153.7 million in 2024, then surged by 42.68% to $185.9 million in 2025.
  • Its last three reported values are $185.9 million in Q3 2025, $191.7 million for Q2 2025, and $185.5 million during Q1 2025.